Sustained Release Excipients Market Overview
The Sustained Release Excipients Market is expanding as pharmaceutical manufacturers increasingly seek advanced materials that can control drug-release profiles, improve bioavailability, and support patient adherence. The rising prevalence of chronic diseases, growing demand for patient-centric therapies, and continued investment in drug delivery technologies are driving the adoption of sustained-release formulations.
According to the Market Research Future report updated August 24, 2026, the Sustained Release Excipients Market was valued at USD 1.50 billion in 2024 and is projected to grow from USD 1.62 billion in 2025 to USD 3.498 billion by 2035, registering a CAGR of 8.0% during 2025–2035. North America remains the largest regional market, supported by strong pharmaceutical R&D activity and the presence of major pharmaceutical companies, while Asia-Pacific is identified as the fastest-growing region. Gelatin currently dominates the product-type segment, while Polymers are emerging as the fastest-growing category. Oral administration holds the largest route share, while Transdermal delivery is the fastest-growing route. Targeted Delivery represents the largest technology segment, while Microencapsulation is projected to grow most rapidly.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/reports/sustained-release-excipients-market-22077
Key players driving innovation and competitiveness in the Sustained Release Excipients Market include:
BASF SE
Evonik Industries AG
Ashland Global Holdings Inc.
Dow Inc.
JRS Pharma
Colorcon Inc.
FMC Corporation
Gattefossé
Merck KGaA
Shin-Etsu Chemical Co., Ltd.
The Sustained Release Excipients Market is being shaped by increasing demand for advanced drug delivery systems and formulations that can provide prolonged therapeutic effects while reducing dosing frequency. Advances in material science are enabling the development of polymers and biocompatible materials with customized release characteristics. Regulatory support for novel formulations is also encouraging pharmaceutical manufacturers to invest in new excipient technologies. At the same time, growing R&D investment in complex formulations, personalized medicine, and targeted therapies is creating additional demand for high-performance excipients.
The Sustained Release Excipients Market can be segmented by product type, route of administration, technology, and region. By product type, the market includes Gelatin, Polymers, Minerals, Sugars, and Others. By route of administration, it covers Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Others. By technology, the market includes Targeted Delivery, Microencapsulation, Wurster Technique, and Others, while the regional market covers North America, Europe, Asia-Pacific, and the Rest of the World.
Opportunities are emerging through biodegradable excipients, novel polymer systems, microencapsulation technologies, and specialized excipients for chronic-disease therapies. Pharmaceutical companies are also increasingly collaborating with excipient manufacturers to develop customized formulations. Advances in 3D printing and nanotechnology could further enable precise control over drug-release profiles, while growing pharmaceutical manufacturing capabilities in Asia-Pacific are creating opportunities for regional suppliers.
Recent Developments and Market Trends:
The growing emphasis on patient-centric drug delivery is increasing demand for sustained-release formulations that reduce dosing frequency and improve medication adherence.
Advances in polymer science and biocompatible materials are enabling excipients with more precise and customizable drug-release characteristics.
Microencapsulation technology is gaining traction because it can improve drug stability, bioavailability, and controlled-release performance across complex formulations.
Pharmaceutical manufacturers are increasing investment in novel excipients to support advanced formulations for chronic diseases, personalized medicine, and targeted therapies.
The development of biodegradable excipients is creating opportunities for more sustainable pharmaceutical formulations while supporting innovation in controlled drug delivery.
Reasons to Buy the Report:
Understand the market size, growth trajectory, CAGR, and forecast valuation through 2035.
Identify the dominant and fastest-growing product type, administration route, and technology segments.
Evaluate North America’s market leadership and Asia-Pacific’s rapid growth potential.
Analyze the competitive landscape and product-development strategies of leading excipient manufacturers.
Assess emerging opportunities in biodegradable materials, polymers, microencapsulation, and advanced drug delivery technologies.
Future Outlook:
The Sustained Release Excipients Market is expected to maintain strong growth through 2035 as pharmaceutical companies increasingly focus on controlled drug delivery, patient adherence, and advanced formulation technologies. Gelatin currently represents the dominant product category because of its established pharmaceutical applications, biocompatibility, and ease of processing, while Polymers are positioned as the fastest-growing category because of their versatility and ability to provide tailored release profiles. Oral administration is expected to remain the largest route because of its convenience, widespread use, and strong patient acceptance, while Transdermal delivery is projected to experience rapid expansion as non-invasive and patient-friendly delivery systems gain traction. Targeted Delivery is expected to remain the largest technology segment because of its established applications in precision drug delivery, while Microencapsulation is projected to be the fastest-growing technology as pharmaceutical manufacturers seek improved stability, bioavailability, and controlled-release performance. North America is expected to retain its leadership because of strong pharmaceutical R&D investment, established drug-development infrastructure, and the presence of major pharmaceutical companies. Europe will remain an important market supported by its aging population and demand for novel drug delivery systems, while Asia-Pacific is projected to remain the fastest-growing region as healthcare infrastructure expands, pharmaceutical manufacturing increases, and demand for advanced medicines rises. Overall, the Sustained Release Excipients Market is projected to reach approximately USD 3.498 billion by 2035 at a CAGR of 8.0%.
➤➤Explore Our Latest Related Reports:
